We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.81B
AUM Growth
+$244M
Cap. Flow
-$21.2M
Cap. Flow %
-0.56%
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35

Top Buys

Rank Stock Value
1
VRCA icon
Verrica Pharmaceuticals
VRCA
+$66.8M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$63.1M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$56.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$31.2M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$107M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$34.2M
4
ANAB icon
AnaptysBio
ANAB
+$24.7M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Industrials 0.65%
3 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIDX
51
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$14M 0.37%
+686,922
New +$14.4M
LKFT
52
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$13.9M 0.36%
150,875
-55,430
-27% -$5.38M
SRRA
53
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$13.3M 0.35%
112,500
-12,500
-10% -$1.25M
VRTX icon
54
Vertex Pharmaceuticals
VRTX
$123B
$12.9M 0.34%
75,898
-76,000
-50% -$11.8M
ABEOW
55
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$12.8M 0.34%
1,259,636
– –
TDOC icon
56
Teladoc Health
TDOC
$1.66B
$11.3M 0.3%
195,000
-325,000
-63% -$15.9M
WVE icon
57
Wave Life Sciences
WVE
$1.12B
$10.8M 0.28%
282,798
-180,000
-39% -$7.75M
VYNE icon
58
VYNE Therapeutics
VYNE
$10.1M 0.26%
345
-99
-22% -$3.85M
SYBX
59
DELISTED
Synlogic
SYBX
$9.27M 0.24%
62,857
– –
MDGL icon
60
Madrigal Pharmaceuticals
MDGL
$12.6B
$9.01M 0.24%
32,213
-110,309
-77% -$19.4M
XERS icon
61
Xeris Biopharma Holdings
XERS
$1.45B
$8.54M 0.22%
+450,000
New +$8.74M
AXGN icon
62
Axogen
AXGN
$2.2B
$8.29M 0.22%
+165,000
New +$7.27M
FLXN
63
DELISTED
Flexion Therapeutics, Inc.
FLXN
$7.96M 0.21%
307,989
– –
CLSD
64
DELISTED
Clearside Biomedical
CLSD
$7.6M 0.2%
47,172
-507
-1% -$85.5K
MRNS
65
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.42M 0.17%
226,933
– –
TBIO
66
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$6.33M 0.17%
+500,000
New +$6.04M
OMED
67
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$6.05M 0.16%
2,620,897
– –
ASMB icon
68
Assembly Biosciences
ASMB
$498M
$5.91M 0.15%
12,558
-27,161
-68% -$14.4M
CDNA icon
69
CareDx
CDNA
$1.83B
$5.72M 0.15%
467,676
-573,000
-55% -$6.57M
FOMX
70
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.6M 0.15%
1,117,324
– –
OCGN icon
71
Ocugen
OCGN
$403M
$5.51M 0.14%
36,721
– –
ARWR icon
72
Arrowhead Research
ARWR
$12.1B
$4.97M 0.13%
365,445
– –
TSRO
73
DELISTED
TESARO, Inc.
TSRO
$4.45M 0.12%
+100,000
New +$4.86M
AVEO
74
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.27M 0.11%
189,119
-56,693
-23% -$1.34M
MTEM
75
DELISTED
Molecular Templates, Inc.
MTEM
$3.79M 0.1%
48,276
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
  • Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
  • Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
  • Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
  • Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.